News

Lymphoma Action respond to frequently asked questions about the COVID-19 vaccines

New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with follicular lymphoma.

Venetoclax plus obinituzumab is now available on the NHS throughout the UK for people with CLL who have not been treated before.

Tazemetostat, the first in a new class of drugs, shows promising efficacy and a favourable safety profile in people with relapsed or refractory follicular lymphoma.

Updated guidelines give recommendations for treatment of people with Waldenström’s macroglobulinaemia.

New report finds two thirds of blood cancer patients are concerned about accessing the most effective treatment.

New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with CLL.

Lenalidomide plus rituximab is now available on the NHS in Scotland for relapsed or refractory follicular lymphoma, while ibrutinib has been approved for NHS use in people with relapsed or refractory Waldenström’s macroglobulinaemia.

Lymphoma Action ensure that the patient voice is heard at HTAs, resulting in better access to the latest treatments.

The National Institutes for Health and Care Excellence (NICE) has approved polatuzumab vedotin for use on the NHS in people with diffuse large B-cell lymphoma (DLBCL).